Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Silo Pharma received confirmation from Nasdaq that it has regained compliance with the minimum closing bid price requirement as of June 17, 2026, closing the matter on its listing status. CEO Eric Weisblum expressed gratitude for investor support and confirmed the company remains on track to advance its lead drug SPC-15 toward a first-in-human clinical trial for PTSD.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.